Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Increase in Online Prescriptions During COVID-19 Pandemic

Key Points: Traditional pharmacy services make getting prescriptions complicated. Pharmacies turned to online models during the pandemic. Pharmaserve allows customers to get their prescriptions filled online. Commentary: Getting your prescription medication can be a pain, especially when it requires you to go into a pharmacy to go and get it. But more options are…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Increase in Online Prescriptions During COVID-19 Pandemic

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Key Points:

  • Traditional pharmacy services make getting prescriptions complicated.
  • Pharmacies turned to online models during the pandemic.
  • Pharmaserve allows customers to get their prescriptions filled online.

Commentary:

Getting your prescription medication can be a pain, especially when it requires you to go into a pharmacy to go and get it. But more options are starting to appear like Pharmaserve, a Canadian-based online pharmaceutical platform that allows consumers to get their prescriptions refilled online rather than having to stand in line at your local pharmacy. We asked Seun Bammeke, Managing Director of Pharmaserve, how they have been able to manage the pain in the process of buying prescription pills online. Like everything in the past year and a half, online versions of anything have become more popular. We also asked Bammeke how the hyper-focus of making everything socially distant or contact-free helped speed up users’ adoption of their services.

Abridged Thoughts:

We sell and ship prescription medication to the United States, so there are typically often many pain points. However, we’ve been able to eliminate a lot of them for our customers. So, for example, since we do not have a physical location, our costs are substantially less than your typical brick and mortar brick and mortar pharmacy apologies. And so, because of that, we are able to pass on a lot of the savings directly onto our customers, which means they’re even cheaper medications for that.

Well, fortunately, the pharmacy has always been fully online. However, our customers’ adoption rate has increased dramatically due to the current world pandemic. We have proven to our patients and prospective patients, they’re able that we are able to provide them with a safe way of delivering their medications while ensuring that it is affordable to our patients. Companies throughout this pandemic have found ways to step up and fill in a void where it is needed and, in turn, made some even more successful or well known.

With Merck’s COVID Antiviral Announcement, Can the Pharma Pipeline Build Treatment Momentum?

What is Behind the “Mergers & Acquisitions” Boom in Healthcare?

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512